… with erlotinib, which accounted for over 98% of lung cancer … least one prescription with a
generic name of “Erlotinib HCL.” … in NSCLC was continually developing over our study time …

… 8 was originally published, data from this study suggest that patients with ERBB mutations
are … is the second most common histological subtype of non-small cell lung cancer (NSCLC) …

… or erlotinib. The incidence of T790M in the gefitinib/erlotinib cohort in the present study was
… by the anatomic location and tumor volume. Comparing the T790M positivity of the present …

… also caused ILD in 4.6% of Japanese patients in phase II studies (11-13). In this study, severe
ILD was reported in 1 of the 50 patients in the erlotinib group; although the incidence was …

… This study aimed to investigate the efficacy and safety of erlotinib plus … In this study, we
compared patient groups treated with erlotinib plus bevacizumab with those treated with erlotinib …

… In this study, the NCI-H1975 cell line harboring double … study only studied the synergistic
effect of β-elemene on the antitumor activity of erlotinib in TKI-resistant H1975 lung cancer cells …

… This study aimed to develop erlotinib (ELB)-loaded poly(ε-caprolactone) nanocapsules (NC
ELB ) and evaluated their in vitro cytotoxicity in A549 cells. The formulation was …

… in MET diagnostic (+) patients as defined in the current study was not reversed by emibetuzumab
plus erlotinib or emibetuzumab monotherapy. Emibetuzumab was well tolerated, and a …

… Asian non-small cell lung cancer (NSCLC) … research, we found that β-elemene combined
with erlotinib enhanced the cytotoxicity of erlotinib to primary EGFR-TKI-resistant NSCLC cells …

… The purpose of this study was to investigate the impact of anticancer drug erlotinib-randomly …
Phase solubility study showed erlotinib displayed maximum solubility in RAMEB CD …